Archive: 13/11/2018
Immunotherapy combination and chemotherapy show encouraging results in Phase II acute myeloid leukemia study
A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute ...
Nov 13, 2018